





Fund Features: (Data as on 31st December'20)

Category: Dynamic Asset Allocation or

Balanced Advantage

Monthly Avg AUM: ₹1,263.91 Crores Inception Date: 10th October 2014

**Fund Managers:** 

Equity Portion: Mr. Arpit Kapoor and Mr. Sumit Agrawal (w.e.f. 01/03/17) **Debt Portion:** Mr. Arvind Subramanian

(w.e.f. 09/11/2015)

Standard Deviation (Annualized): 13.94%

Modified Duration: 2.15 years\* Average Maturity: 2.66 years\* Macaulay Duration: 2.23 years\* Yield to Maturity: 4.18%\* \*Of Debt Allocation Only

Benchmark: 50% S&P BSE 200 TRI + 50% NIFTY AAA Short Duration Bond Index (w.e.f 11/11/2019)

Asset allocation:

Gross Equity<sup>^</sup> (Including Arbitrage): 66.44%

**Debt:** 33.56% **Net Equity:** 37.14% **Market Cap Split: Large Cap:** 74.86%

Mid and Small Cap: 25.14%

Minimum Application Amount: ₹5,000/- and any amount thereafter

Exit Load: In respect of each purchase of Units:

- For 10% of investment: Nil
- For remaining investment: 1% if redeemed/ switched out within 1 year from the date of allotment (w.e.f. July 5, 2017)

SIP Frequency: Monthly (Investor may choose any day of the month except 29th, 30th and 31st as the date of instalment.)

Options Available: Growth, Dividend (Payout, Reinvestment and Sweep (from Equity Schemes to Debt Schemes only))

PLAN	DIVIDEND RECORD DATE	₹/UNIT	NAV
REGULAR	18-Dec-20	0.12	12.1700
	15-Jun-20	0.10	10.4300
	28-Jan-20	0.15	11.3200
	18-Dec-20	0.13	13.1400
DIRECT	15-Jun-20	0.11	11.1900
	28-Jan-20	0.16	12.0800

Face Value per Unit (in ₹) is 10

Dividend is not guaranteed and past performance may or may not be sustained in future. Pursuant to payment of dividend, the NAV of the scheme would fall to the extent of payout and statutory levy (as applicable)

## **IDFC DYNAMIC EQUITY FUND**

An open ended dynamic asset allocation fund

## **FUND PHILOSOPHY\***

IDFC Dynamic Equity Fund is a hybrid fund with active equity allocation changing based on the trailing P/E of Nifty 50 index. The fund has a pre-defined model which indicates the range of active equity allocation based on P/E levels, and there are 6 different range of equity allocation possible. Higher the P/E band, lower will be the active equity allocation and vice versa.

Change of bands happen once a month while changes within the band happen dynamically on a day to day basis. The active equity portfolio is managed like a diversified fund. Active stock selection philosophy combines quality stocks with good growth potential. The quality filters for the fund are - conversion of EBIDTA to operating cash - OCF as % of EBIDTA > 33%; Moderate leverage: Debt EBIDTA <3x; Profitability: EBIDTA / Net operating Assets >30%. Thus, companies which qualify these parameters and have higher visibility of growth versus peers will form the core portfolio. Depending on P/E levels, the fund can have more large or mid/small cap names. The fund will also use Nifty futures to dynamically manage active equity allocation within a month.

The debt portion of the fund is actively managed. The portfolio emphasizes on maintaining high credit quality and currently has 100% in AAA or equivalent instruments. Further the portfolio is oriented towards short-to-medium duration strategies.

Bloomberg Nifty P/E data as of 31st December 2020 indicates a value of 33 and equity band for the month of January will continue to be 30-40%

## OUTLOOK

- With the spread of the pandemic and the lockdown during Q1 FY21, earnings for the year FY21 were sharply downgraded.
- However, the swifter than expected economic recovery led to a more robust Q2 FY21.
- Upgrades exceeded downgrades 3x, a rarity, after years of earnings disappointment.
- FY21 estimates, quickly rebounded from negative to positive territory, despite the Q1 debacle.
- The fall during Mar'20 lasted less than 35 trading days, erasing between 36-43% across the indices - Large, Mid and Small Caps. Supportive action from Central Banks was quicker.
- As investors searched for stable earnings, rotation from one sector to another, as exhibited from Apr-Dec'20 phase was evident.
- Staples after outperforming in Mar-Apr, have underperformed since then. Pharma and IT services outperformed during May-Sept; Banks/NBFC, after underperforming from Mar-Sept,20; outperformed during Oct-Dec'20.
- After the debacle of Mar'20, Small caps outshone the rest of the market - for the first time since CY17.
- If economic recovery is robust and RBI does not move aggressively into high real interest zone, Small caps could benefit the most.

The above mentioned is the current strategy of the Fund Manager. However, asset allocation and investment strategy shall be within broad parameters of Scheme Information Document.


Ratios calculated on the basis of 3 years history of monthly data.



I OKII OLIO		
Name of the Instrument Ratings	% to NAV	1
Equity and Equity related Instruments Net Exposure Software	66.44% 37.14% 8.02%	E
Infosys	6.28%	i
Infosys - Equity Futures	-1.40%	F
Tech Mahindra	2.22%	F
Tech Mahindra - Equity Futures	-1.19%	F
Tata Consultancy Services	2.17%	1
Tata Consultancy		E
Services - Equity Futures	-2.18%	E
Wipro HCL Technologies	0.99% 0.71%	(
Larsen & Toubro Infotech	0.71%	l
Banks	6.80%	4
ICICI Bank	4.56%	7
ICICI Bank - Equity Futures	-1.15%	í
HDFC Bank	3.39%	5
Axis Bank	1.38%	5
Axis Bank - Equity Futures	-1.39%	5
Finance	5.56%	1
Muthoot Finance	1.96%	Ş
Muthoot Finance - Equity Futures	-0.17%	F
Bajaj Finserv	1.14%	F
Bajaj Finserv - Equity Futures HDFC Life Insurance Company	-0.51% 0.82%	ŀ
Cholamandalam Invt and Fin Co	0.82%	(
Bajaj Finance	0.60%	ı
Mas Financial Services	0.43%	ı
Aavas Financiers	0.38%	Ċ
ICICI Securities	0.10%	
ICICI Lombard General Insurance		F
Company	0.06%	1
Consumer Non Durables	5.14%	(
Hindustan Unilever	1.92%	F
Hindustan Unilever - Equity Futures Nestle India	-0.06% 1.73%	(
Burger King India	1.75%	L
Dabur India	0.65%	L
Dabur India - Equity Futures	-0.66%	ı
Tata Consumer Products	0.40%	i.
Tata Consumer Products -		1
Equity Futures	-0.40%	3
Pharmaceuticals	4.62%	1
Divi's Laboratories	2.27%	(
Divi's Laboratories - Equity Futures	-0.39%	F
Aurobindo Pharma	2.02% -0.86%	F
Aurobindo Pharma - Equity Futures Cipla	1.91%	١
Cipla - Equity Futures	-1.91%	F
Alkem Laboratories	1.02%	١
Dr. Reddy's Laboratories	0.59%	(
Dr. Reddy's Laboratories - Equity Future		5
IPCA Laboratories	0.58%	7
Auto Ancillaries	3.26%	(
MRF	0.94%	L
MRF - Equity Futures	-0.37%	H
Minda Industries	0.93%	1
Balkrishna Industries	0.62%	(

Name of the Instrument	Ratings	% to NAV
Balkrishna Industries - Equit	-0.55%	
Sandhar Technologies		0.58%
Endurance Technologies		0.56%
Tube Investments of India		0.54%
Petroleum Products	3.21%	
Reliance Industries		5.30%
Reliance Industries - Equity	Futures	-2.09%
Telecom - Services		2.69%
Bharti Airtel	3.26%	
Bharti Airtel - Equity Future	-0.56%	
Cement	2.28%	
UltraTech Cement	1.20%	
JK Cement		1.09%
Ambuja Cements	0.47%	
Ambuja Cements - Equity F	utures	-0.47%
Industrial Products SRF		<b>1.83%</b> 0.84%
Shaily Engineering Plastics		0.62%
Supreme Industries		0.62%
AIA Engineering		0.54%
SRF - Equity Futures		-0.78%
Pesticides		0.66%
PI Industries		0.66%
Healthcare Services		0.59%
Gland Pharma		0.59%
Gas		0.59%
Indraprastha Gas	.+	0.68%
Indraprastha Gas - Equity Fu	lures	-0.21% <b>0.43%</b>
Chemicals Chemcon Speciality Chemic	0.43%	
Retailing	0.43%	
Avenue Supermarts	0.42%	
Construction	0.42%	
PNC Infratech	0.35%	
Construction Project		0.33%
Larsen & Toubro	1.88%	
Larsen & Toubro - Equity Fu	-1.89%	
KEC International	itures	0.33%
Index		-9.52%
Nifty 50 Index - Equity Futu	res	-9.52%
Treasury Bill	103	9.00%
364 Days Tbill - 2021	SOV	5.62%
182 Days Tbill - 2021	SOV	3.38%
Corporate Bond	30 V	7.80%
Reliance Industries	AAA	3.06%
Power Finance Corporation	AAA	1.97%
NABARD	AAA	1.58%
REC	AAA	1.18%
NTPC	AAA	0.02%
Government Bond	7.56%	
5.22% - 2025 G-Sec	SOV	3.80%
7.17% - 2028 G-Sec	SOV	3.76%
Commercial Paper		3.63%
LIC Housing Finance A1+		1.82%
HDFC	A1+	1.82%
Net Cash and Cash Equivale	5.57%	
Grand Total	100.00%	
rotal		.50.0070







Investors understand that their principal will be at High risk

This product is suitable for investors who are seeking\*:

- To create wealth over long term
- Dynamic allocation towards equity, derivatives, debt and money market instruments

\*Investors should consult their financial advisers if in doubt about whether the product is suitable for them.

MUTUAL FUND INVESTMENTS ARE SUBJECT TO MARKET RISKS, READ ALL SCHEME RELATED DOCUMENTS CAREFULLY.







